NervGen Pharma
Develops NVG-291 for spinal-cord injury.
$2.27
After-hours close0.00 (0.00%)
At close$2.27(−2.78%)
Something off on this page? Send us feedback.
Breakdown13F · Form 4
Institutions 2.06%Insiders —
Shares outstanding 82.19M · Float 64.35M · 78.3% free float
Insiders — no current Form 4 position.
Institutions13F, as of Mar 31, 2026
45 holders · 1.69M shares · 44 new positions · 44 increased · 0 reduced · 0 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| PFG Investments, LLC | 201.0K | 0.24% | +201.0Knew | Apr 27, 2026 |
| Bank of America Corp /DE/ | 200.7K | 0.24% | +200.7Knew | May 18, 2026 |
| Marshall Wace, LLP | 200.4K | 0.24% | +200.4Knew | May 15, 2026 |
| Royal Bank of Canada | 172.0K | 0.21% | +172.0Knew | May 15, 2026 |
| Integrated Wealth Concepts LLC | 86.8K | 0.11% | +86.8Knew | May 15, 2026 |
| Valley Forge Investment Consultants Inc Adv | 77.7K | 0.09% | +77.7Knew | Apr 21, 2026 |
| Bank of Montreal /Can/ | 62.9K | 0.08% | +62.9Knew | May 13, 2026 |
| Captrust Financial Advisors | 62.4K | 0.08% | +62.4Knew | May 15, 2026 |
Beneficial owners13D/G · 5% or more, as filed
No 13D/G filer at 5% or more on record.
InsidersForm 4
No current Form 4 position on record.
3 people have not refiled in the last 18 months (960.2K shares), so they are not in the figure above
Latest trades
Nothing filed in the last 12 months.
CongressHouse and Senate disclosures
Not reported.